Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trofinetide - Neuren Pharmaceuticals

Next Previous
Drug Profile

Trofinetide - Neuren Pharmaceuticals

Alternative Names: G-2Me-PE; Glycyl-2-methyl-L-prolyl-L-glutamic acid; Glycyl-L-2-methylprolyl-L-glutamic acid; NNZ-2566

Latest Information Update: 30 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuren Pharmaceuticals
  • Developer Neuren Pharmaceuticals; Rettsyndrome.org; Walter Reed Army Institute of Research
  • Class Anti-inflammatories; Glutamates; Neuropeptides; Neuroprotectants; Oligopeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Cytokine inhibitors; Free radical modulators; Glial cell modulators; Neuropeptide receptor modulators; Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome; Rett syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Rett syndrome
  • Phase II Brain injuries; Fragile X syndrome
  • No development reported Autistic disorder; Multiple sclerosis

Most Recent Events

  • 16 Jun 2020 Neuren Pharmaceuticals re-initiates the phase III LAVENDER trial in Rett syndrome (In adolescents, In children) in USA (NCT04181723)
  • 02 Apr 2020 Neuren Pharmaceuticals has patent protection for trofinetide in Israel
  • 03 Mar 2020 The US FDA grants Rare Pediatric Disease (RPD) designation to trofinetide for Rett syndrome
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial

Legal

Back to top